Digitizing Healthcare – Embracing change. Creating opportunity.

Emily Wyatt

The future of healthcare is digital

For many industries, embracing digitization has become a matter of survival. Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace.

In comparison with other industries, healthcare has been slow to take advantage of the digital revolution. Traditionally healthcare has always been a difficult industry in which to innovate; it is highly regulated, expensive, complex and risk averse. However, rising drug development costs, increased patient expectations, and a growing dependence on health resources, place the industry under increasing pressure to move with the times. Many organizations with an interest in health, including the pharmaceutical industry, medical technology companies, health insurers, and payers are focusing on the digital world. However, the strongest digital health innovators are now coming in from outside the industry.

How tech companies are driving digital transformation

Healthcare represents an incredibly lucrative opportunity for traditional technology companies. The tech giants – Alphabet (the parent company of Google), Amazon, Apple, Microsoft and IBM – are taking the lead and heavily investing their time, resource and talent into healthcare.

Each of the major tech companies are using their core business strengths to create digital health initiatives across a variety of platforms. These are being implemented at every touchpoint of the patient/health professional journey ranging from data storage, artificial intelligence (AI), e-commerce, voice-enabled solutions, consumer apps and wearables. By developing tools that patients and health professionals embrace, and through collaborations with healthcare providers, the Big 5 are poised to reinvent the healthcare industry.

Digitizing Healthcare White Paper from Deallus
DOWNLOAD WHITEPAPER

About the author

Emily Wyatt

Emily is a Senior Associate based in the London office. Since joining Deallus, Emily has lead research for top tier pharmaceutical clients supporting their global strategy to implement personalised healthcare initiatives across the value chain. She has also facilitated competitive simulation workshops looking at the impact of Tech disruption in healthcare. Emily has significant experience across a variety of therapeutic areas and industries including neuroscience, oncology, immune-oncology, companion diagnostics, liver diseases, autoimmune diseases and personalised healthcare.

Emily holds a MPhil in Bioscience Enterprise from the University of Cambridge and a BSc Honours in Biochemistry from the University of Bristol. Throughout her career, Emily has also developed strong expertise in the medical devices space, having led business development projects for medical device companies in oncology and inflammatory diseases.

You may also be interested in…

  • Leading in a Crisis: Driving Value for Your Customers, Your Organization, and Yourself

Episode 2: Leading in a crisis

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

Remdesivir’s journey and its impact on share price

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry. In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. Our infographic plots significant events in Remdesivir’s recent history to contextualize this dramatic story and the seemingly disproportionate impact one product’s journey appeared to have on the overall company stock price.

OnDemand Webinar – Navigating Market Disruption after COVID-19

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

Deallus Virtual Workshop on Competitive Insight at EyeforPharma 2020

What is a ‘competitive insight’? How do you make it actionable? These were the two key questions we focused on at EyeForPharma. Competitive Insights are the secret sauce that generate Competitive Advantage from Strategic Intelligence and point to opportunities of impact where it matters most. We offered participants a compressed but unique hands-on experience of generating competitive insights and focused on understanding how to make them truly actionable.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan - Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer